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Abstract X-linked adrenoleukodystrophy is a demyelinating
disorder of the central nervous system with an impaired very long
chain fatty acid metabolism. The adrenoleukodystrophy gene
encodes a peroxisomal membrane protein that is part of a family
of related ATP-binding transporters including the adrenoleuko-
dystrophy-related protein. The adrenoleukodystrophy protein
and adrenoleukodystrophy-related protein show 66% identity
and have a mirror expression in most mouse tissues. We show
that retroviral-mediated adrenoleukodystrophy-related gene
transfer corrects very long chain fatty acid accumulation in
adrenoleukodystrophy fibroblasts, irrespective of the presence or
absence of adrenoleukodystrophy protein. Pharmacological
approaches aiming at overexpressing the adrenoleukodystro-
phy-related gene in the central nervous system of adrenoleuko-
dystrophy patients might thus offer new therapeutic leads.
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1. Introduction
Adrenoleukodystrophy (ALD) is a neurodegenerative disor-
der characterized by progressive demyelination within the cen-
tral nervous system (CNS), adrenal insu⁄ciency and accumu-
lation of very long chain fatty acids (VLCFA) due to an
impairment of their L-oxidation in peroxisomes [1]. The
ALD gene encodes a 75 kDa peroxisomal membrane protein
(ALDP) which belongs to a family of ATP-binding cassette
(ABC) transporters [2,3]. These ABC transporters are part of
a large family that includes the cystic ¢brosis transmembrane
conductance receptor and the multiple drug resistance glyco-
proteins [3]. The latter occur as single functional proteins with
two related halves. In contrast, ALDP and other peroxisomal
transporters are hemi-transporters that need to dimerize to
exert an import function. ALD has three homologs that are
also located in the peroxisomal membrane: the ALD-related
(ALDR) protein (66% identity) [4,5], the more distantly re-
lated PMP70 protein (38% identity to ALDP) [6,7] and the
PMP70 related (P70R) protein (27% identity to ALDP) [8,9].
Among peroxisomal ABC transporter genes, ALD is the only
one known to be associated with a disease. Soon after the
ALD gene was discovered, two closely related hemi-transport-
er genes were cloned in yeast (Pxa1p and Pxa2p) [10,11].
Studies of mutants in these genes have provided signi¢cant
clues about the function of ALDP. In yeast, long chain fatty
acids (LCFA) are ¢rst activated into CoA derivatives within
the cytosol by a LCFA-CoA synthetase and then imported
across the peroxisomal membrane by Pxa1p and Pxa2p het-
erodimers [11^13]. It is therefore hypothesized that ALDP
forms homodimers and/or heterodimers with ALDR,
PMP70 or P70R proteins to control the transport of
VLCFA-CoA into peroxisomes.
Mice with a targeted mutation in the ALD gene have not
yet developed a clinical phenotype and demyelination at 1 year
of age, in spite of accumulation of VLCFA in the brain and
adrenal gland as well as a decrease in the L-oxidation activity
in vitro [14^16]. Gene redundancy could account for these
observations if another ABC peroxisomal transporter could
partially compensate for the ALD defect in mice. ALDR pro-
tein (ALDRP) is an attractive candidate for two reasons: (1)
it shows the highest identity (66%) to ALDP [4,5] and (2)
ALDRP and ALDP have a mirror expression in most mouse
tissues [17], suggesting that both proteins might ful¢l similar
metabolic functions in di¡erent tissues. This prompted us to
examine whether the expression of the ALDR gene can cor-
rect the metabolic defect of ALD ¢broblasts, irrespective of
the presence or absence of mutated ALDP.
2. Materials and methods
2.1. Cell culture
Skin ¢broblasts obtained from ALD patients and the psi-CRIP
packaging cell line were cultured in Dulbecco’s modi¢ed Eagle’s me-
dium (Gibco) supplemented with 10% inactivated fetal calf serum
(Gibco) and 4 mM glutamine.
2.2. Construction and packaging of the retroviral vector MFG-mALDR
Mouse ALDR (mALDR) pTL2 cDNA [18] was inserted into the
MFG vector (Somatix Therapy Corporation, Alameda, CA, USA)
under the control of the Mo-MLV LTR promoter. To position the
initiation ATG codon of the mALDR cDNA at the position normally
occupied by the viral env ATG, mouse ALDR cDNA was ampli¢ed
from the plasmid pTL2 with the 5P-GCAAGCCATGGTA-CA-
CATGCTAAAT-3P and 5P-CAAGGGATCCTTAGGATGTCTTT-
TCTGG-3P primers to create NcoI and BamHI sites at the 5P and
3P end of the cDNA. The PCR reaction was run in the GeneAmp
PCR System 2400 (Perkin Elmer) with 2.5 U Expand High Fidelity
PCR System (Boehringer), 0.2 mM of each dNTP, expand HF bu¡er
with 1.5 mM MgCl2, 1 mM of the two primers, 30 ng of the template
DNA, in a ¢nal volume of 100 Wl (25 cycles of 94‡C for 30 s, 55‡C for
30 s, 72‡C for 3 min). NcoI and BamHI sites were then used to insert
the PCR product into the MFG vector.
The MFG-mALDR and PGK-Neo vector containing the neomy-
cin-resistance gene [19] were co-transfected into the amphotropic
packaging cell line psi-CRIP using DNA/calcium phosphate precipi-
tation as described [19]. Transfected cells were selected in a medium
containing 1 mg/ml G418 and clones were isolated by ring cloning and
expanded to cell lines. MFG-mALDR producer clones were selected
on the basis of a positive immuno£uorescence assay with anti-
ALDRP antibodies and the capacity to transduce ALD patients ¢-
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broblasts in an infection assay. The M48-ALD-producer psi-CRIP
cells have been described elsewhere [19]. The absence of helper virus
was assayed by a virus mobilization assay [19].
2.3. Retroviral gene transfer
Supernatant from a con£uent monolayer of the highest producer
MFG-mALDR and M48-ALD [19] clones were harvested 24 h after a
medium change, ¢ltered and used for the infection of ALD skin ¢-
broblasts in the presence of polybrene, 8 Wg/ml (Sigma). Infection was
performed three times in 24 h. As determined by Southern blotting,
infection of ALD skin ¢broblasts with MFG-mALDR vector resulted
in the integration of approximately one provirus copy per cell genome
(not shown).
2.4. Immunocytochemistry
Human skin ¢broblasts were cultured for 16 h in the wall of a
chamber slide (Nunc), ¢xed in 2% formaldehyde for 4 min and per-
meabilized in phophate-bu¡ered saline (PBS)/0.1% Triton X-100.
Cells were then incubated at room temperature with mouse mono-
clonal (1D6) [20] or rabbit polyclonal antibodies (1693) [21] against
human ALDP, rabbit polyclonal antibodies against mouse (7373) [17]
or human (1872) ALDRP and/or rabbit anti-human catalase poly-
clonal antibody (Chemicon).
All secondary antibodies were obtained a⁄nity pure from Jackson
Immunoresearch as follows: FITC or Cy3 conjugated goat anti-
mouse IgG (H+L) and Cy3 or FITC conjugated donkey anti-rabbit
IgG (H+L). The double procedures followed the principles of recog-
nition of antibody species and the speci¢city by the conjugates. Ap-
propriate ¢lters for each £uorochrome and combined ¢lters for £uo-
rescein and Cy3 were used on a light microscope equipped with
£uorescence (Nikon Optiphot-2).
2.5. Determination of VLCFA levels
VLCFA concentrations were measured in cultured skin ¢broblasts
after 2 weeks by gas/liquid chromatography/mass spectrometry [21].
(3,3,5,5-2H4)-docosanoic (C22:0-d4) and (3,3,5,5-2H4) hexacosanoic
(C26:0-d4) acids (gift from Dr H.J. ten Brink, Amsterdam, The
Netherlands) were used as internal standard. Ions at m/z 397, m/z
401, m/z 453 and m/z 457 corresponding to the [M-57] ions of 22:0,
22:0-d4, 26:0 and 26:0-d4 TBDMS (butyldimethylsilyl) derivatives
were selectively monitored using electron impact. The corresponding
peaks were integrated and the content of C22:0 and C26:0 fatty acids
was calculated according to a calibration curve using C22-d4 and C26-
d4 as internal standards. Results were expressed as C26:0/C22:0
ratios.
3. Results
3.1. Retroviral transduction of mouse ALDR cDNA corrects
the VLCFA metabolism in ALD ¢broblasts
To evaluate if the ALDR gene expression could correct the
metabolic defect in ALD ¢broblasts, we constructed a re-
combinant retroviral vector, MFG-mALDR, carrying the
mouse ALDR cDNA under the control of the LTR promoter
of the MFG vector. Protein alignments demonstrate a 93.5%
amino acid identity between mouse and human ALDR genes
[5]. Skin ¢broblasts from three di¡erent ALD patients were
transduced with supernatant from MFG-mALDR or M48-
ALD producer psi-CRIP cells.
The ALD-1 cell line is a SV40-transformed cell line [19]
with a R617H mutation leading to the absence of ALDP, as
determined by Western-blotting and immunocyto£uorescence
with anti-ALDP antibody [22]. The ALD-2 cell line is a non-
transformed cell line with a R518W mutation that leads to a
decreased ALDP immunoreactivity, likely due to an instabil-
ity of the protein [22]. The ALD-3 cell line is a non-trans-
formed cell line with a large deletion of the ALD gene that
leads to no detectable ALD mRNA and absence of ALDP
[2,23]. The ALDR gene is expressed at a very low level in
normal or ALD skin ¢broblasts with no detectable ALDRP,
as assayed by Western-blotting or immunocyto£uorescence
[17] (Fig. 1A).
After transduction with the MFG-mALDR vector, a
marked punctate £uorescent staining appeared in the ALD-
1, ALD-2 and ALD-3 cell lines (Fig. 1B). A similar punctate
pattern was observed when these cell lines were transduced
with the M48-ALD vector (Fig. 1C). The anti-ALDP and
anti-ALDRP staining co-localized with structures immuno-
stained with anti-catalase (not shown), demonstrating the cor-
rect peroxisomal targeting of the vector-encoded proteins. Im-
munocyto£uorescence with anti-ALDP antibody of the ALD-
1 and ALD-2 cell lines transduced with the MFG-mALDR
vector showed no detectable ALDP staining, indicating that
overexpression of ALDRP did not stabilize instable mutated
ALDP (not shown).
Based on immunocyto£uorescence with anti-ALDRP anti-
bodies, 99% of ALD-1, 75% of ALD-2 and 85% of ALD-3
¢broblasts expressed ALDRP after three cycles of infection.
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Fig. 1. Expression of ALDRP and ALDP in ALD ¢broblasts after
transduction with MFG-mALDR and M48-ALD vectors. (A) Prior
to transduction, the ALD-3 cell line shows no ALDRP or ALDP
immunostaining after incubation with antibodies against human
ALDRP (polyclonal 1872) and ALDP (mAb 1D6). The same cells
show ALDRP or ALDP expression with peroxisomal localization
after transduction with the MFG-mALDR (B) or M48-ALD (C)
vectors.
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Similarly, using anti-ALDP antibodies, 100% of ALD-1, 96%
of ALD-2 and 78% of ALD-3 ¢broblasts expressed ALDP
after three cycles of infection. We have previously demon-
strated that retroviral-mediated transfer of the ALD cDNA
with the M48-ALD vector corrects the VLCFA metabolism in
ALD ¢broblasts [19]. To evaluate the functional complemen-
tation of ALD ¢broblasts with mouse ALDR cDNA, VLCFA
concentrations were measured in ALD ¢broblasts before and
after transduction with MFG-mALDR and M48-ALD vec-
tors. Table 1 shows that the C26:0/C22:0 ratio of the untrans-
duced transformed ALD-1 cell line is 3-fold of that of normal
transformed ¢broblasts. Infection with MFG-mALDR or
M48-ALD vectors normalized the C26:0/C22:0 ratio in these
¢broblasts. Similarly, the non-transformed ALD-2 and ALD-
3 ¢broblasts showed before transduction a 5^7.5-fold increase
of the C26:0/C22:0 ratio that decreased to normal or near
normal values after transduction with the MFG-mALDR or
M48-ALD vectors.
Next, we wished to compare the e⁄cacy of the MFG-
mALDR and M48-ALD vectors to correct the VLCFA accu-
mulation in ALD ¢broblasts. Because the percentage of cells
expressing ALDRP or ALDP varied between experiments, we
designed a mixing experiment to check that a modi¢cation of
the C26:0/C22:0 ratio in ¢broblasts is proportional to the
percentage of normal and ALD cells. The C26:0/C22:0 ratio
was determined in a pool of ALD ¢broblasts with 20, 40, 60
and 80% of control cells. As the proportion of control cells
increased, the C26:0/C22:0 ratio decreased proportionally
(r2 = 0.997) (Fig. 2). The linearity of the assay allowed thus
to calculate by simple linear regression the expected C26:0/
C22:0 values of transduced cells with MFG-mALDR or M48-
ALD vectors with respect to the number of cells expressing
the vector-encoded ALDRP or ALDP, as determined by im-
munocyto£uorescence. The correction of the C26:0/C22:0 ra-
tio was slightly greater than expected after normalization of
the C26:0/C22:0 ratio with respect to the number of cells
expressing a vector-encoded ALDRP or ALDP (Table 1).
Vector-encoded ALDP and ALDRP were expressed at the
same level in transduced cells, as determined by Western-blot-
ting (not shown). Overexpression of ALDP or ALDRP most
likely increases the import of VLCFA in peroxisomes of trans-
duced cells and leads to an increased degradation of these
fatty acids in these cells. No signi¢cant di¡erence in the e⁄-
cacy of correction of the VLCFA metabolism was observed in
the three studied ALD cells transduced with the MFG-
mALDR or M48-ALD vectors.
4. Discussion
Our study demonstrates that overexpression of ALDR
cDNA can correct the accumulation of VLCFA in ALD ¢-
broblasts, con¢rming recent published data by Kemp et al.
[24]. In the latter study however, the correction of the VLCFA
metabolism was achieved in a mixed population of ALD cells
with di¡erent mutations of the ALD gene. One could not
therefore discard the possibility that, in these experiments,
some ALD cells were corrected while other were not, owing
to the presence or absence of mutated ALD protein in the
peroxisomal membrane. In our experiments, we did not ob-
serve any di¡erence in the correction of VLCFA accumulation
after overexpression of ALDRP in ALD cell lines whose ALD
gene mutation leads to a complete absence of ALD mRNA
and ALDP or to the presence of non-functional but yet nor-
mally targeted ALDP in peroxisomes. Our data therefore
demonstrate, conclusively, that overexpression of the ALDR
gene corrects to the same extent the biochemical defect of
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Fig. 2. The C26:0/C22:0 ratio in a mixed cell population. Control
and ALD ¢broblasts were counted and then mixed in the ratio indi-
cated. The C26:C22:0 ratio per 1U105 cells is plotted versus the
percentage of control cells in the mixture.
Table 1
Correction of the VLCFA metabolism in ALD ¢broblasts with MFG-mALDR and M48-ALD vectors
n Observed C26:0/C22:0 ratioa Expected C26:0/C22:0 ratiob
Control SV-40 ¢broblasts 4 0.178 þ 0.030 0.178
Untransduced ALD-1 3 0.494 þ 0.014
ALD-1 transduced with MFG-mALDR vector 4 0.159 þ 0.011 0.177 (99%)
ALD-1 transduced with M48-ALD vector 3 0.143 þ 0.015 0.178 (100%)
Control ¢broblasts 20 0.082 þ 0.028 0.082
Untransduced ALD-2 3 0.395 þ 0.014
ALD-2 transduced with MFG-mALDR vector 4 0.136 þ 0.012 0.160 (75%)
ALD-2 transduced with M48-ALD vector 2 0.055 þ 0.017 0.094 (96%)
Untransduced ALD-3 3 0.607 þ 0.022
ALD-3 transduced with MFG-mALDR vector 4 0.090 þ 0.010 0.161 (85%)
ALD-3 transduced with M48-ALD vector 3 0.113 þ 0.009 0.197 (78%)
aThe C26:0/C22:0 ratio is given as the mean þ S.D. of three determinations of the number (n) of studied samples.
bThe expected C26:0/C22:0 ratio is calculated by linear regression for the fraction (given in percentage in parentheses) of cells expressing vector-
encoded ALDP or ALDRP, as detected by immunocyto£uorescence.
E. Flavigny et al./FEBS Letters 448 (1999) 261^264 263
ALD, irrespective of the presence or absence of mutant ALD
protein. Our results suggest in addition that heterodimers did
not form signi¢cantly between functional ALDRP or ALDP
and non-functional ALDP, arguing against a negative trans-
dominant e¡ect of mutated ALDP over ALDRP or ALDP
wild-type proteins. In yeast, Pxa1p and Pxa2p, two orthologs
of ALDP and ALDRP involved in the import of long chain
fatty acid-CoA, were shown to heterodimerize, the absence of
Pxa2p leading to destabilization of Pxa1p [12]. Because ALDP
could heterodimerize with ALDRP, it is therefore possible
that overexpression of ALDRP could stabilize an instable
mutated form of ALDP. However, after infection with the
MFG-mALDR vector, ALDP remained undetectable by im-
munocyto£uorescence in the ALD-2 cell line whose ALD gene
mutation leads to a decreased amount of ALDP, likely re£ect-
ing instability. These results demonstrate that overexpression
of the ALDR gene corrects per se the biochemical defect of
ALD and that ALD and ALDR proteins did not form sig-
ni¢cant heterodimers in vitro in ¢broblasts.
The ALD mouse shows no clinical phenotype, despite ac-
cumulation of VLCFA in the brain and adrenal glands similar
to that observed in ALD patients [14^16]. ALDR gene redun-
dancy could account for these observations. ALDRP and
ALDP are both markedly expressed in astrocytes, oligoden-
drocytes and microglia in mouse [25] and a double mutant of
ALD and ALDR genes might therefore be required to mimic
the human ALD in mice. In contrast, the ALDR gene expres-
sion is very low in human [4,5]. We, however, recently found
that, in human, the ALDR gene is expressed at a low level in
neurons, astrocytes and microglia (unpublished results), rais-
ing the possibility that the stimulation of ALDR gene expres-
sion in these cells as well as in oligodendrocytes could com-
pensate for the loss of ALDP.
Kemp et al. [24] showed recently that 4-phenyl butyrate
treatment of human ALD cells and ALD mice results in de-
creased levels of VLCFA in cells, brain and adrenal glands.
The correction of the VLCFA metabolism was associated with
an increased expression of the ALDR gene and a 2.4-fold
increase in the number of peroxysomes. This e¡ect was how-
ever transitory in ALD mice (K. Smith, personal communica-
tion). Feno¢brate, a peroxisome proliferator, stimulates the
ALDR gene expression in rat liver [26]. It is however likely
that peroxisome proliferators will have little e¡ects in ALD
patients for two reasons: (1) although feno¢brate has recently
been shown to increase the transaminase gene expression in
human cells [27], there is, to our knowledge, no report dem-
onstrating that peroxisome proliferators could induce signi¢-
cantly the expression of peroxisomal genes in human, in con-
trast to rodents; (2) the e¡ect of peroxisome proliferators on
the gene expression is minimal in rodent brain [28], likely due
to the inability of these compounds to cross the blood-brain
barrier e⁄ciently. The demonstration that overexpression of
ALDRP can correct the VLCFA metabolism in ALD cells
supports, however, the active screening of drugs that would
allow upregulation of the ALDR gene in CNS cells of ALD
patients. Such e¡ort would open the possibility to correct
pharmacologically the biochemical defect of ALD in the brain
of ALD patients.
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